Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. (March 2016)

• Record Type: Journal Article
• Authors: Salahuddin, Usman I; Pandey, Ambarish; Ayers, Colby R; See, Raphael; Neeland, Ian J; Gore, M Odette; Grinsfelder, D Bennett; Abdullah, Shuaib M; Khera, Amit; de Lemos, James A; McGuire, Darren K
• Is Part Of: Diabetes & vascular disease research. Volume 13:Number 2(2016:Mar.)
• Page Start: 113
• Page End: 118
• Publication Date: 2016-03
• Subjects: Rosiglitazone -- high-sensitivity cardiac troponin -- diabetes mellitus -- cardiovascular disease; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/1479164115618517
• Languages: English
• ISSNs: 1479-1641

Abstract

Objective: To assess the impact of intermediate-term treatment with rosiglitazone on high-sensitivity cardiac troponin T levels among patients with type 2 diabetes mellitus with or at high risk of coronary artery disease. Methods: High-sensitivity cardiac troponin T level was measured at baseline and after 6 months of study treatment in a randomized trial comparing rosiglitazone versus placebo in patients with type 2 diabetes and prevalent cardiovascular disease or multiple cardiovascular disease risk factors. Univariable and multivariable linear regression analyses were performed to assess the effect of rosiglitazone versus placebo on high-sensitivity cardiac troponin T levels. Results: The study included 150 randomized participants, of whom 106 had paired baseline and end-of-study blood samples for analysis (mean age: 56 ± 8 years, 42% women; 8.8 years average type 2 diabetes duration; mean haemoglobin A1c of 7.5). Almost all study participants (93%) had detectable high-sensitivity cardiac troponin T (⩾3 ng/L) at baseline, including 23% with high-sensitivity cardiac troponin T levels exceeding the threshold commonly used to diagnose myocardial infarction (⩾14 ng/L). Change in high-sensitivity cardiac troponin T levels from baseline to follow-up was not significantly different between rosiglitazone and placebo groups ( p = 0.316). Conclusion: Rosiglitazone did not impact high-sensitivity cardiac troponin T levels, adding to the growing body of literature suggesting that the incremental heart failure risk associated with rosiglitazone is not mediated by direct myocardial injury.